Nova Ev To Sales vs Capex To Depreciation Analysis

NLH Stock

CAD 0.25 0.01 3.85%

Nova Leap financial indicator trend analysis is infinitely more than just investigating Nova Leap Health recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nova Leap Health is a good investment. Please check the relationship between Nova Leap Ev To Sales and its Capex To Depreciation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nova Leap Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Ev To Sales vs Capex To Depreciation

Ev To Sales vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nova Leap Health Ev To Sales account and Capex To Depreciation. At this time, the significance of the direction appears to have weak relationship.

The correlation between Nova Leap's Ev To Sales and Capex To Depreciation is 0.37. Overlapping area represents the amount of variation of Ev To Sales that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Nova Leap Health, assuming nothing else is changed. The correlation between historical values of Nova Leap's Ev To Sales and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Sales of Nova Leap Health are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Ev To Sales i.e., Nova Leap's Ev To Sales and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

0.37

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most indicators from Nova Leap's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nova Leap Health current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nova Leap Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Nova Leap's Selling General Administrative is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to climb to 21.18 in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	3.3M	11.0M	26.6M	27.9M
Cost Of Revenue	14.1M	18.2M	16.8M	9.8M

Total Operating Expenses Cost Of Revenue

Nova Leap fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Net Receivables	Good Will	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Long Term Debt Total	Other Current Liab	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total
Total Assets		0.88	0.99	0.24	-0.37	0.93	0.79	0.25	0.91	1.0	0.69	0.87	0.82	0.92	0.85	0.9	0.99	0.88	-0.11	0.88	0.95	0.78	0.9	0.81	0.95	0.73
Total Current Liabilities	0.88		0.8	-0.2	-0.62	0.95	0.87	0.49	0.93	0.87	0.68	0.98	0.99	0.97	0.99	0.95	0.82	0.98	-0.06	0.99	0.9	0.89	0.65	0.88	0.94	0.78
Total Stockholder Equity	0.99	0.8		0.39	-0.25	0.88	0.69	0.11	0.88	0.99	0.67	0.79	0.73	0.86	0.76	0.84	1.0	0.79	-0.11	0.79	0.93	0.72	0.92	0.72	0.91	0.64
Net Tangible Assets	0.24	-0.2	0.39		0.65	0.02	-0.26	-0.69	0.08	0.26	0.05	-0.24	-0.31	-0.05	-0.26	-0.05	0.35	-0.24	-0.08	-0.24	0.17	-0.18	0.47	-0.24	0.06	-0.26
Retained Earnings	-0.37	-0.62	-0.25	0.65		-0.5	-0.63	-0.71	-0.32	-0.37	-0.5	-0.64	-0.67	-0.47	-0.65	-0.39	-0.32	-0.66	-0.08	-0.66	-0.37	-0.68	-0.21	-0.64	-0.51	-0.63
Accounts Payable	0.93	0.95	0.88	0.02	-0.5		0.85	0.37	0.95	0.92	0.67	0.94	0.91	0.97	0.93	0.93	0.89	0.93	-0.18	0.94	0.98	0.86	0.77	0.85	0.99	0.74
Cash	0.79	0.87	0.69	-0.26	-0.63	0.85		0.75	0.75	0.76	0.53	0.95	0.85	0.9	0.86	0.87	0.71	0.95	-0.25	0.89	0.8	0.77	0.71	1.0	0.86	0.95
Long Term Debt	0.25	0.49	0.11	-0.69	-0.71	0.37	0.75		0.27	0.21	0.29	0.62	0.5	0.48	0.49	0.46	0.13	0.62	-0.05	0.54	0.28	0.48	0.18	0.73	0.4	0.83
Net Receivables	0.91	0.93	0.88	0.08	-0.32	0.95	0.75	0.27		0.9	0.65	0.9	0.87	0.96	0.89	0.96	0.87	0.88	-0.08	0.9	0.96	0.8	0.7	0.76	0.94	0.68
Good Will	1.0	0.87	0.99	0.26	-0.37	0.92	0.76	0.21	0.9		0.7	0.86	0.81	0.91	0.84	0.88	0.99	0.86	-0.1	0.87	0.95	0.78	0.9	0.79	0.95	0.7
Other Stockholder Equity	0.69	0.68	0.67	0.05	-0.5	0.67	0.53	0.29	0.65	0.7		0.65	0.6	0.65	0.62	0.64	0.69	0.62	0.54	0.64	0.72	0.9	0.61	0.56	0.73	0.58
Total Liab	0.87	0.98	0.79	-0.24	-0.64	0.94	0.95	0.62	0.9	0.86	0.65		0.96	0.97	0.97	0.95	0.8	1.0	-0.13	0.99	0.89	0.87	0.68	0.95	0.94	0.89
Short Long Term Debt	0.82	0.99	0.73	-0.31	-0.67	0.91	0.85	0.5	0.87	0.81	0.6	0.96		0.92	1.0	0.91	0.76	0.96	-0.09	0.98	0.83	0.85	0.56	0.86	0.88	0.74
Total Current Assets	0.92	0.97	0.86	-0.05	-0.47	0.97	0.9	0.48	0.96	0.91	0.65	0.97	0.92		0.94	0.99	0.86	0.96	-0.16	0.96	0.96	0.84	0.75	0.91	0.97	0.83
Short Term Debt	0.85	0.99	0.76	-0.26	-0.65	0.93	0.86	0.49	0.89	0.84	0.62	0.97	1.0	0.94		0.92	0.79	0.97	-0.1	0.99	0.87	0.86	0.6	0.87	0.9	0.75
Intangible Assets	0.9	0.95	0.84	-0.05	-0.39	0.93	0.87	0.46	0.96	0.88	0.64	0.95	0.91	0.99	0.92		0.83	0.93	-0.09	0.93	0.93	0.82	0.71	0.88	0.93	0.8
Common Stock	0.99	0.82	1.0	0.35	-0.32	0.89	0.71	0.13	0.87	0.99	0.69	0.8	0.76	0.86	0.79	0.83		0.8	-0.1	0.81	0.93	0.74	0.92	0.73	0.92	0.65
Short Long Term Debt Total	0.88	0.98	0.79	-0.24	-0.66	0.93	0.95	0.62	0.88	0.86	0.62	1.0	0.96	0.96	0.97	0.93	0.8		-0.15	0.99	0.88	0.85	0.68	0.95	0.93	0.88
Other Current Liab	-0.11	-0.06	-0.11	-0.08	-0.08	-0.18	-0.25	-0.05	-0.08	-0.1	0.54	-0.13	-0.09	-0.16	-0.1	-0.09	-0.1	-0.15		-0.11	-0.12	0.27	-0.18	-0.23	-0.13	-0.1
Net Debt	0.88	0.99	0.79	-0.24	-0.66	0.94	0.89	0.54	0.9	0.87	0.64	0.99	0.98	0.96	0.99	0.93	0.81	0.99	-0.11		0.88	0.86	0.64	0.9	0.92	0.82
Non Current Assets Total	0.95	0.9	0.93	0.17	-0.37	0.98	0.8	0.28	0.96	0.95	0.72	0.89	0.83	0.96	0.87	0.93	0.93	0.88	-0.12	0.88		0.84	0.83	0.81	0.99	0.72
Non Currrent Assets Other	0.78	0.89	0.72	-0.18	-0.68	0.86	0.77	0.48	0.8	0.78	0.9	0.87	0.85	0.84	0.86	0.82	0.74	0.85	0.27	0.86	0.84		0.63	0.78	0.88	0.73
Other Assets	0.9	0.65	0.92	0.47	-0.21	0.77	0.71	0.18	0.7	0.9	0.61	0.68	0.56	0.75	0.6	0.71	0.92	0.68	-0.18	0.64	0.83	0.63		0.73	0.83	0.67
Cash And Short Term Investments	0.81	0.88	0.72	-0.24	-0.64	0.85	1.0	0.73	0.76	0.79	0.56	0.95	0.86	0.91	0.87	0.88	0.73	0.95	-0.23	0.9	0.81	0.78	0.73		0.87	0.95
Common Stock Shares Outstanding	0.95	0.94	0.91	0.06	-0.51	0.99	0.86	0.4	0.94	0.95	0.73	0.94	0.88	0.97	0.9	0.93	0.92	0.93	-0.13	0.92	0.99	0.88	0.83	0.87		0.79
Non Current Liabilities Total	0.73	0.78	0.64	-0.26	-0.63	0.74	0.95	0.83	0.68	0.7	0.58	0.89	0.74	0.83	0.75	0.8	0.65	0.88	-0.1	0.82	0.72	0.73	0.67	0.95	0.79

Click cells to compare fundamentals

Nova Leap Account Relationship Matchups

Nova Leap fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.1M	17.5M	26.8M	23.9M	27.5M	28.9M
Total Current Liabilities	4.7M	4.2M	6.2M	4.0M	4.6M	3.5M
Total Stockholder Equity	7.1M	9.8M	18.5M	18.7M	21.5M	22.6M
Net Tangible Assets	(3.2M)	(1.7M)	(304.1K)	1.6M	1.8M	1.9M
Retained Earnings	(3.4M)	(2.1M)	(357.0K)	(1.2M)	(1.1M)	(1.1M)
Accounts Payable	941.8K	946.1K	1.3M	1.2M	1.4M	762.4K
Cash	1.6M	2.8M	1.7M	1.3M	1.5M	1.3M
Long Term Debt	2.0M	2.8M	896.1K	117.5K	135.1K	128.4K
Net Receivables	1.7M	1.4M	3.9M	2.4M	2.8M	1.5M
Good Will	9.4M	10.2M	16.7M	16.0M	18.4M	19.4M
Other Stockholder Equity	1.6M	1.6M	1.8M	2.1M	2.5M	1.6M
Total Liab	7.0M	7.7M	8.3M	5.3M	6.1M	4.9M
Short Long Term Debt	3.5M	2.7M	4.0M	2.4M	2.7M	2.4M
Total Current Assets	3.5M	4.3M	6.0M	4.0M	4.6M	3.0M
Short Term Debt	3.6M	2.9M	4.3M	2.7M	3.1M	2.5M
Intangible Assets	811.3K	1.3M	2.1M	1.1M	1.3M	909.5K
Common Stock	9.0M	10.3M	17.1M	19.0M	21.8M	22.9M
Short Long Term Debt Total	5.7M	6.0M	6.2M	4.0M	4.6M	4.3M
Other Current Liab	93.6K	19.3K	127.7K	57.5K	51.8K	103.3K
Net Debt	4.1M	3.2M	4.5M	2.7M	3.1M	2.9M
Non Current Assets Total	10.6M	13.2M	20.8M	20.0M	23.0M	12.1M
Other Assets	134.3K	1.3M	729.1K	1.3M	1.5M	1.6M
Cash And Short Term Investments	1.6M	2.8M	1.7M	1.3M	1.5M	1.4M
Common Stock Shares Outstanding	48.5M	60.9M	66.4M	77.7M	89.3M	57.0M
Liabilities And Stockholders Equity	14.1M	17.5M	26.8M	23.9M	27.5M	15.4M
Non Current Liabilities Total	2.3M	3.5M	2.1M	1.3M	1.5M	1.7M
Accumulated Other Comprehensive Income	(120.5K)	92.3K	(80.6K)	(1.2M)	(1.1M)	(1.0M)
Property Plant And Equipment Net	271.3K	395.3K	1.3M	1.5M	1.7M	1.8M
Net Invested Capital	12.6M	15.4M	23.4M	21.2M	24.3M	15.8M
Net Working Capital	(1.3M)	159.9K	(264.5K)	(10.4K)	(11.9K)	(12.5K)
Property Plant Equipment	271.3K	395.3K	1.3M	1.5M	1.7M	1.8M
Capital Stock	9.0M	10.3M	17.1M	19.0M	21.8M	14.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Nova Stock Analysis

When running Nova Leap's price analysis, check to measure Nova Leap's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Leap is operating at the current time. Most of Nova Leap's value examination focuses on studying past and present price action to predict the probability of Nova Leap's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Leap's price. Additionally, you may evaluate how the addition of Nova Leap to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC